Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT04849364 2025-05-31

PERSEVERE

Phase 2 Terminated

52 enrolled 16 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06992336 2025-05-28

Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy

Phase 2 Recruiting

411 enrolled

Breast

Breast Neoplasms

NCT04198727 2025-05-23

DPDMAX

Phase 2 Active not recruiting

155 enrolled

Breast

Breast Neoplasm Malignant Female

NCT01349088 2025-05-02

Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer

Phase 1/2 Withdrawn

Breast

Breast Neoplasms

Clinical Trials

Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer

Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

EVOLVE-BDT

Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer

A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

JAZMINE

PLANET

The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

MECCA

Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study

SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study

TARMAC

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

BRIGHT

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

CAPELA

INSIGHT

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer

SOLARA

BRE-08

Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

SASCIA

CAPPA

DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment

Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)

Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer

The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC

NeoADAPT

AMBRE

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer

PRECIOUS

Phase II Study to Assess the Efficacy of ASLAN001 Plus Capecitabine in CNS Metastases for HER2+ Breast Cancer

ALPHABET

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

Capecitabine as Maintenance Therapy vs Observation in Early-stage Triple-negative Breast Cancer

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)

TAC Versus TCX as Adjuvant Treatment for High-risk Her2-Negative Breast Cancer

Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer

Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients

TUGETHER

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

PERSEVERE

Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy

DPDMAX

Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer